B. Pro, R. Advani, and P. Brice, Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study, Journal of Clinical Oncology, vol.30, issue.18, pp.2190-2196, 2012.
DOI : 10.1200/JCO.2011.38.0402

C. Bossard, M. Dobay, and M. Parrens, Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels, Blood, vol.124, issue.19, pp.2983-2986, 2014.
DOI : 10.1182/blood-2014-07-584953

E. Sabattini, M. Pizzi, and V. Tabanelli, CD30 expression in peripheral T-cell lymphomas, Haematologica, vol.98, issue.8, pp.81-82, 2013.
DOI : 10.3324/haematol.2013.084913

URL : http://doi.org/10.3324/haematol.2013.084913

S. Horwitz, R. Advani, and N. Bartlett, Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin, Blood, vol.123, issue.20, pp.3095-3100, 2014.
DOI : 10.1182/blood-2013-12-542142

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425442

M. Duvic, M. Tetzlaff, and P. Gangar, Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis, Journal of Clinical Oncology, vol.33, issue.32, pp.3759-3765, 2015.
DOI : 10.1200/JCO.2014.60.3787

Y. Kim, M. Tavallaee, and U. Sundram, Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and S??zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project, Journal of Clinical Oncology, vol.33, issue.32, pp.3750-3758, 2015.
DOI : 10.1200/JCO.2014.60.3969

J. Vose, J. Armitage, and D. Weisenburger, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes, J Clin Oncol, vol.26, issue.25, pp.4124-4130, 2008.

K. Savage, N. Harris, and J. Vose, ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project, Blood, vol.111, issue.12, pp.5496-5504, 2008.
DOI : 10.1182/blood-2008-01-134270

V. Mak, J. Hamm, and M. Chhanabhai, Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors, Journal of Clinical Oncology, vol.31, issue.16, pp.311970-1976, 2013.
DOI : 10.1200/JCO.2012.44.7524

E. Jacobsen, J. Sharman, and Y. Oki, Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression, Blood, vol.125, issue.9, pp.1394-1402, 2015.
DOI : 10.1182/blood-2014-09-598763

T. Illidge, R. Bouabdallah, and R. Chen, Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma, Leukemia & Lymphoma, vol.2013, issue.1, pp.703-710, 2015.
DOI : 10.1182/blood-2012-03-418673

B. Pro, R. Advani, and P. Brice, Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma, Blood, vol.124, issue.21, 2014.